# Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study

> **NCT07026604** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Cavernous Malformation, Cerebral

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT07026604
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07026604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07026604, "Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07026604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*